The exact catalogue entry is Porcine Parvovirus Vaccine, Inactivated (Strain S-1) Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions. The material is a bulk-processed antigen stream derived from whole porcine parvovirus strain S-1 propagated in a continuous porcine cell substrate, harvested, clarified, concentrated, inactivated, and buffer-exchanged for downstream formulation. The phrase “Veterinary Grade API” positions the material as an active substance for licensed veterinary medicinal products, not as a finished immunisation product. No harmonised model code exists across regulatory jurisdictions; when a model designation is required in a batch record, it is assigned by the manufacturer as an internal material code tied to the virus seed lot, passage level, inactivation campaign, and buffer system. A model field might therefore read “PPV-S1-API-VG” in purchasing documents, but that string is not a regulatory identifier. The dosage-form list includes tablets, capsules, granules, and premix; however, the intact inactivated virion is biologically incompatible with direct compression, encapsulation, and unprotected oral delivery. The list is therefore a classification span rather than a demonstration of oral solid-dose efficacy.

Product identity and release specification boundaries

Porcine parvovirus is a non-enveloped, single-stranded DNA virus of the family Parvoviridae, with an icosahedral capsid diameter of 18–25 nm. The S-1 strain identity is confirmed by VP2 nucleotide sequencing or monoclonal antibody typing, not by morphological inspection alone. The API is a particulate colloid, not a true molecular solution; its stability is governed by pH, ionic strength, residual host-cell protein load, and temperature. For release as a veterinary active substance, the analytical panel addresses identity, sterility, mycoplasma, inactivation safety, residual moisture, and potency. The limits in the following table are typical of a lyophilised or frozen liquid antigen concentrate used in injectable or reconstitutable presentations; the controlling specification is the finished-product marketing authorisation.

The potency boundary of 1.0–2.0 relative potency units is measured against the producer’s reference batch and should not be interpreted as a fixed antigen mass. Published data for this specific S-1 configuration may be limited; therefore, the finished-product dossier must contain batch-to-batch consistency data generated in the target species if the route or adjuvant differs from the reference product. Non-compliance in any release test requires batch rejection or re-processing only if the validated process allows it. Re-processing of inactivated antigen concentrates is generally limited to repeat sterile filtration or buffer exchange; re-inactivation is not acceptable because it may alter epitope density.

Formulation of the inactivated S-1 antigen into injectable presentations requires aseptic mixing with adjuvant systems, commonly aluminium hydroxide gel or oil-in-water emulsion, under controlled low-shear conditions. The virus particle has a diameter of 18–25 nm and can pass through 0.22 µm membranes, but terminal filtration after adjuvant addition is usually impossible; sterile filtration is therefore performed on the antigen stream before adjuvanting or on the buffer system. Low-protein-binding polyvinylidene fluoride or polyethersulfone capsules are used because charge-mediated membrane adsorption removes virus and lowers haemagglutination titre. Liquid presentations are maintained at pH 7.0–7.6 and stored at 2–8 °C; pH excursions below 6.0 or above 8.0 induce aggregation and loss of conformational epitopes. For freeze-dried presentations, the liquid antigen is formulated with sucrose, trehalose, or hydrolysed porcine gelatin and lyophilised to residual moisture ≤ 3.0 % w/w. The resulting cake is reconstituted with water for injection; the reconstituted suspension must be used within the in-use holding period defined by the finished-product licence. The API is generally not supplied as a simple solution for oral or parenteral use without further formulation; it is an antigen concentrate that requires a downstream manufacturing step.

When tablet, capsule, granule, or premix formats are requested rather than parenteral liquids

Direct compression tableting or hard gelatin capsule filling of unmodified inactivated porcine parvovirus antigen is not supported by licensed efficacy data. The viral capsid is a proteinaceous assembly that is denatured by gastric acidity and intestinal proteases, and the immune response required for protection of the porcine embryo depends on systemic neutralising antibody after parenteral administration. Published data for this specific configuration are limited. If an oral powder, granule, or feed premix format is proposed, the antigen would require multi-stage enteric protection, lyophilisation with cryoprotectants, and possibly encapsulation in liposomes or polymeric carriers; no harmonised dissolution or antigen-release monograph exists for this product. The tablet/capsule/granule/premix terms in the catalogue should therefore be read as the manufacturer’s dosage-form classification range, not as a claim that the unprocessed API can be directly tableted or encapsulated. The practical downstream presentations of this inactivated S-1 antigen are injectable suspensions, aqueous solutions where the formulation is a solution, and freeze-dried powders for reconstitution; granules and premixes would be experimental or custom manufacturing projects requiring target-animal immunogenicity bridging.

Comparative strain selection: S-1, NADL-2, Kresse, and VP2 subunit antigens

Whole-virus S-1 inactivated antigen differs from other porcine parvovirus products by virus strain, process format, and DIVA compatibility. Strain identity is confirmed by VP2 sequencing; published comparative efficacy data between S-1 and reference strains such as NADL-2 or Kresse are limited, so equivalence cannot be assumed without a bridging immunogenicity study in gilts or sows. Whole-virus products present conformational epitopes on the assembled capsid, while VP2 subunit antigens contain the major capsid protein only and may require higher antigen mass or more potent adjuvants to achieve comparable serological response. Whole-virus S-1 is compatible with combination vaccines containing erysipelas and leptospira fractions only when antigen recovery and potency of each fraction are confirmed after blending; incompatibility can occur if leptospira bacterins shift the ionic strength or if preservatives such as thimerosal are added. Whole-virus inactivated vaccines are not suitable for NS1-based DIVA serology because field infection and vaccination cannot be distinguished by NS1 antibody if the assay is used in unvaccinated populations. The choice of S-1 over other strains is therefore driven by regional licensing precedent and seed availability, not by intrinsic superiority.

In sow vaccination programmes, the finished product manufactured from this API is given by intramuscular injection to replacement gilts and sows before breeding to reduce embryonic death, mummification, stillbirth, and delayed returns to oestrus caused by porcine parvovirus. A conventional primary course consists of two doses separated by 3–4 weeks, with the second dose given at least 2 weeks before first service; booster administration is given before each subsequent gestation. The API is not administered directly. The final dose volume, age at first vaccination, and revaccination interval are fixed by the finished-product marketing authorisation, not by the API supplier. At farm level, failure to complete the primary course before first service is a recognised operational risk because maternal antibody from natural exposure can interfere with active immunisation in gilts with high titre. Handling of the API inside the manufacturing facility requires aseptic transfer in a laminar-flow cabinet or closed single-use bioprocessing system. Liquid concentrate is stored at 2–8 °C unless frozen storage has been validated; lyophilised API is stored at 2–8 °C and protected from humidity. Opening lyophilised containers at relative humidity above 60 % may raise residual moisture and shorten reconstitution stability. Repeated freeze-thaw cycles of liquid antigen beyond 3 cycles produce aggregation and haemagglutination titre loss; freeze-thaw cycling should be avoided unless the stability protocol supports it.

What process and storage boundary conditions preserve antigen integrity on production-scale equipment?

Upstream production of porcine parvovirus strain S-1 is performed in stirred-tank microcarrier bioreactors or fixed-bed single-use systems using a susceptible porcine cell substrate. Virus yield varies with cell density, multiplicity of infection, and harvest timing; production harvest is typically initiated at 72–96 h post-infection when cell viability has declined but before host-cell debris increases the purification burden. Early harvest lowers yield; late harvest raises residual host-cell protein and DNA. Clarification uses depth filtration followed by 0.45 µm membrane filtration. Tangential flow filtration with polyethersulfone cassettes of 300–500 kDa nominal molecular weight cutoff concentrates the virus while removing medium proteins, but transmembrane pressure above 1.0 bar promotes gel-layer formation and titre loss; low-shear positive-displacement pumps are used rather than high-shear centrifugal pumps. Inactivation is performed with binary ethylenimine or formaldehyde under conditions validated to achieve at least 4 log10 infectivity reduction and confirmed by blind passage in susceptible porcine cells for a minimum of 3 passages. Residual inactivation agent is neutralised or diafiltered, and the residual concentration is controlled because carryover can destabilise the final formulation. Adjuvant hydration and antigen adsorption are performed in temperature-controlled jacketed vessels at 2–8 °C. If an oil-in-water emulsion adjuvant is used, rotor-stator mixing above 10,000 min−1 may be employed to create the emulsion before antigen addition; the antigen is added after the emulsion is cooled to avoid shear and heat exposure. Lyophilisation cycles are qualified by freeze-drying microscopy or representative product resistance data; the collapse temperature for stabilised S-1 formulations is commonly below −25 °C, so primary drying is run at conservative shelf temperatures. The finished API or final product must not be autoclaved because thermal denaturation destroys neutralising epitopes. Master seed and cell substrate are tested for extraneous porcine viruses, including porcine circovirus type 1 and type 2 and porcine reproductive and respiratory syndrome virus, according to regional monographs. These boundary conditions reflect standard veterinary biologics manufacturing practice; published data for this specific S-1 configuration may be limited, and the approved dossier controls prevail.